Intercept Pharmaceuticals Inc. (ICPT) Given “Positive” Rating at Leerink Swann
Intercept Pharmaceuticals Inc. (NASDAQ:ICPT)‘s stock had its “positive” rating restated by analysts at Leerink Swann in a research report issued to clients and investors on Friday.
Several other research analysts have also recently issued reports on the stock. Wedbush reissued a “buy” rating and set a $239.00 price target on shares of Intercept Pharmaceuticals in a report on Saturday, July 9th. Credit Suisse Group AG reissued a “buy” rating and set a $200.00 price target on shares of Intercept Pharmaceuticals in a report on Friday, August 5th. Laidlaw cut shares of Intercept Pharmaceuticals from a “buy” rating to a “sell” rating and cut their price target for the stock from $345.00 to $105.00 in a report on Friday, August 5th. BMO Capital Markets reissued an “outperform” rating and set a $218.00 price target (down from $219.00) on shares of Intercept Pharmaceuticals in a report on Friday, August 5th. Finally, JMP Securities reissued a “buy” rating on shares of Intercept Pharmaceuticals in a report on Thursday, August 18th. Five research analysts have rated the stock with a sell rating, four have issued a hold rating and eleven have given a buy rating to the company’s stock. Intercept Pharmaceuticals currently has a consensus rating of “Hold” and an average price target of $177.67.
Shares of Intercept Pharmaceuticals (NASDAQ:ICPT) traded up 1.7076% on Friday, hitting $146.5607. The stock had a trading volume of 34,301 shares. Intercept Pharmaceuticals has a one year low of $89.76 and a one year high of $217.99. The stock’s market cap is $3.62 billion. The company’s 50 day moving average is $155.80 and its 200 day moving average is $151.15.
This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at https://www.americanbankingnews.com/2016/10/14/intercept-pharmaceuticals-inc-icpt-given-positive-rating-at-leerink-swann.html
Intercept Pharmaceuticals (NASDAQ:ICPT) last announced its earnings results on Thursday, August 4th. The biopharmaceutical company reported ($3.14) earnings per share for the quarter, topping the consensus estimate of ($3.69) by $0.55. Intercept Pharmaceuticals had a negative net margin of 5,003.95% and a negative return on equity of 50.58%. The business earned $5.52 million during the quarter, compared to the consensus estimate of $1.72 million. During the same quarter in the prior year, the firm earned ($1.99) earnings per share. The business’s quarterly revenue was up 1140.4% compared to the same quarter last year. Equities research analysts predict that Intercept Pharmaceuticals will post ($16.31) EPS for the current fiscal year.
In other Intercept Pharmaceuticals news, CMO David Shapiro sold 411 shares of Intercept Pharmaceuticals stock in a transaction on Monday, October 10th. The shares were sold at an average price of $153.34, for a total value of $63,022.74. Following the transaction, the chief marketing officer now owns 44,272 shares in the company, valued at approximately $6,788,668.48. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, insider Lisa Bright sold 246 shares of Intercept Pharmaceuticals stock in a transaction on Thursday, August 25th. The shares were sold at an average price of $159.00, for a total transaction of $39,114.00. Following the completion of the transaction, the insider now owns 18,460 shares in the company, valued at approximately $2,935,140. The disclosure for this sale can be found here. Corporate insiders own 9.20% of the company’s stock.
Several institutional investors have recently made changes to their positions in ICPT. CENTRAL TRUST Co bought a new position in shares of Intercept Pharmaceuticals during the second quarter worth $107,000. Legal & General Group Plc raised its position in shares of Intercept Pharmaceuticals by 4.5% in the second quarter. Legal & General Group Plc now owns 1,196 shares of the biopharmaceutical company’s stock worth $171,000 after buying an additional 52 shares during the period. Metropolitan Life Insurance Co. NY raised its position in shares of Intercept Pharmaceuticals by 3.2% in the second quarter. Metropolitan Life Insurance Co. NY now owns 1,234 shares of the biopharmaceutical company’s stock worth $176,000 after buying an additional 38 shares during the period. Pacer Advisors Inc. bought a new position in shares of Intercept Pharmaceuticals during the second quarter worth $180,000. Finally, IBM Retirement Fund raised its position in shares of Intercept Pharmaceuticals by 3.6% in the second quarter. IBM Retirement Fund now owns 1,657 shares of the biopharmaceutical company’s stock worth $236,000 after buying an additional 58 shares during the period. Institutional investors own 81.86% of the company’s stock.
Intercept Pharmaceuticals Company Profile
Intercept Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics to treat non-viral, progressive liver diseases. The Company’s product candidates have the potential to treat orphan and more prevalent diseases for which there are limited therapeutic solutions.
Receive News & Ratings for Intercept Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intercept Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.